Midwest Metastatic Breast Cancer Conference. Douglas Yee, M.D. Director Masonic Cancer Center University of Minnesota
|
|
- Tracy Horton
- 6 years ago
- Views:
Transcription
1 Midwest Metastatic Breast Cancer Conference Douglas Yee, M.D. Director Masonic Cancer Center University of Minnesota Presented By: Title Sponsor:
2 Historical Overview & Evolution of Metastatic Breast Cancer Douglas Yee, MD Director, Masonic Cancer Center Professor of Medicine and Pharmacology Midwest Metastatic Breast Cancer Conference November 4, 2017
3 And you may ask yourself Well How did I get here? -Talking Heads (Eno, Frantz, Byrne, Harrison, Weymouth
4 How Did We Learn About Breast Cancer? Estrogen Receptor lucky guess HER2 nagging clinical question Triple-negative breast cancer new technology What s next?
5 Targeted Breast Cancer Therapy Beatson GT Lancet 2:
6 Estrogen and Estrogen Receptor Ovary Ovary Estrogen Receptor Growth Genes - Off Estrogen Estrogen Receptor Growth Genes On!
7 Blocking Estrogen Production Pre-menopausal women make ovarian estrogen Ovary Ovary Stop ovarian function Goserelin/Leuprolide Surgical removal Estrogen Receptor Estrogen Receptor Growth Genes - Off Growth Genes - Off
8 Blocking Estrogen Receptor Function Ovary Block estrogen receptor filling Tamoxifen Fulvestrant Estrogen Receptor Estrogen Receptor Growth Genes - Off Growth Genes - Off
9 Turning Off Estrogen Post-menopausal women still make estrogen Adrenal Adrenal Stop estrogen production Anastrozole Letrozole Exemestane Estrogen Receptor Estrogen Receptor Growth Genes On! Growth Genes - Off
10 Angela M.H. Brodie
11 Inhibition of ERa Function LHRH LH, FSH LHRH Agonists/Antagonists Leuprolide Goserelin Adrenal Peripheral Ovary E1 Oopherectomy E2 Aromatase Inhibitor Anastrazole Letrozole Exemestane SERM Tamoxifen Torimefene Raloxifene Fulvestrant ERa ERE Co-Repressor NCo-R SMRT
12 Other Pathways Activate Estrogen Receptor Cell Signaling Pathways Cell Signaling Pathways Trastuzumab Everolimus Many experimental drugs Estrogen Receptor Estrogen Receptor Growth Genes On! Growth Genes - Off
13 Cross-talk between signal transduction pathways and ER signaling in endocrine-resistant breast cancer, with opportunities for targeted intervention. Johnston S R Clin Cancer Res 2010;16: by American Association for Cancer Research
14 mtor Inhibition (Everolimus/Afinitor ) Enhances ER Targeting Strategies Exemestane Tamoxifen 1 o Resistance 2 o Resistance BOLERO 2 Phase 3 randomized to exemestane with or without everolimus (1:2) Previous treatment for MBC with nonsteroidal AI required TAMRAD Phase 3 randomized to tamoxifen with or without everolimus (1:1) Previous AI treatment required Baselga, et al. N Engl J Med 366: PMID: Bachelot, et al. J Clin Oncol 30: PMID:
15 Making the Lever Harder To Push Make ER lever stiffer Palbociclib Ribociclib Abemaciclib Estrogen Receptor Growth Genes On! Estrogen Receptor Growth Genes - Off
16 The role of CDK 4/6 in cell-cycle progression. Aki Morikawa, and N. Lynn Henry Clin Cancer Res 2015;21: by American Association for Cancer Research
17 Palbociclib/Ibrance Improves Response To Fulvestrant/Faslodex Turner, et al. N Engl J Med 373: PMID:
18 2 nd Drug Approved Ribociclib/Kisqali with Letrozole/Femara Hortobagyi, et al. N Engl J Med 375: PMID:
19 3 rd Drug Approved Abemaciclib/Verzenio Sledge, et al. J Clin Oncol 35: PMID:
20 What s Next For Estrogen Receptor? More anti-estrogens oral fulvestrants Inhibitors of other pathways mtorc1 and mtorc2 Upstream and downstream of mtorc New pathways
21 1980s Why Do Identical Tumors Have Different Rates Of Recurrence? Clark, et al. New England Journal of Medicine 320:627
22 HER2/neu Oncogene Rat neuroblastoma used in 3T3 assay and neu identified in Neu related to Epidermal Growth Factor Receptor superfamily - HER2. Viral oncogene (avian erythroblastosis virus -erbb) related to EGFR family EGFR family members bind to multiple ligands and are transmembrane tyrosine kinases.
23 HER2 Amplification in Node-positive Breast Cancer Any Amplification > 5 copies Disease-free Survival Overall Survival Slamon et al. Science 235:
24 HER2 Amplification in Breast Cancer Green = Centromere Orange= HER2 Pauletti et al. J Clin Oncol 18:
25 Trastuzumab (Herceptin ) Humanized Anti-HER2 Antibody Effective only in HER2 overexpressing or amplified breast cancer Synergy with chemotherapy in metastatic disease Unexpected cardiac toxicity (CHF) observed in clinical trials Slamon, et al. N Engl J Med 344: PMID:
26 How Do Anti-HER2 Therapies Work? Singh, et al. Br J Cancer 2014 PMID:
27 Is Trastuzumab An Immune Therapy? Pohlmann, et al. Clin Cancer Res 15: PMID:
28 HER Family Targeting Prevent dimerization of HER2 with other partners HER2 pertuzumab/perjeta HER3 MM121, LJM716 HER2/3 MCLA128 Inhibit HER family member tyrosine kinase biochemical activity Lapatinib/Tykerb Neratinib/Nerlynx Poziotinib Tucatinib (ONT-380) Antibody drug conjugates Ado-trastuzumab emtansine (Kadcyla, TDM-1) Trastuzumab Deruxtecan (DS-8201a) Antibodies with better immune activation Margetuximab MCLA-128 Combine HER2 targeting with immune enhancers
29 Perou, et al. Proc Natl Acad Sci U S A 96: PMID: 2000s - Molecular Portraits of Breast Cancers Normal Luminal B Claudin-low Basal-like Luminal A HER2-enriched Adapted from Perou
30 Molecular Subtypes Predict Response To Neoadjuvant HER2-based Therapy Carey, et al. J Clin Oncol 34: PMID:
31 What Is Triple Negative Breast Cancer? TNBC 587 TNBC tumors 767 TNBC tumors Before Lehmann, Chen, Shyr, Pietenpol; JCI, 2011 Lehmann, Chen, Shyr, Pietenpol; PLoS One, June, TNBC Subtypes, plus immune phenotyping Courtesy of J. Pietenpol
32 What Is The Immune TNBC Subset? Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, et al. (2016) Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLOS ONE 11(6): e
33 These Are Not The Cells You re Looking For
34 PDL1/PD1 Interactions = Jedi Mind Trick Antibodies Disrupt The Trick PD-1 Pembrolizumab/Keytruda Nivolumab/Opdivo PD-L1 Atezolizumab/Tecentriq Avelumab/Bavencio Durvalumab/Imfinzi Pardoll Nat Rev Cancer 12: PMID:
35 Checkpoint Inhibitors Have Some Activity In TNBC Nanda, et al. J Clin Oncol 34: PMID:
36 UNC 2% Other TNBC subtypes TNBC tumor Luminal/Androgen receptor (LAR) Androgen-receptor signaling and PIK3CA mutations LAR 16% BL1 35% Basal-like 1 (BL1) Elevated expression of cell cycle and DNA damage response genes Mesenchymal (M) Trans-differentiation features and growth factor signaling (FGFR, PDGFR, NOTCH, TGFß) M 24% BL2 22% N=767 Basal-like 2 (BL2) Enriched in select growth factors (MET & EGFR) and myoepithelial cell features Lehmann, Chen, Shyr, Pietenpol; PLoS One, June, 2016 Courtesy of J. Pietenpol
37 Fong, et al. N Engl J Med 361: PMID:
38 Mechanism of action of PARPi. Synthetic Lethal Strategy BRCA Tumors Lack HRR Published by AAAS Christopher J. Lord, and Alan Ashworth Science 2017;355:
39 January 2015 March 2017
40
41 HER2+ Mouse Model Goel, et al. Nature 548: PMID:
42 Why Do Tumors Stop Responding? Breast cancer phenotypes are caused by accumulated genetic abnormalities Exogenous mutagens are not linked to the majority of breast cancers Endogenous source of mutation (APOBECs) frequently expressed in breast cancer
43 APOBEC family 9 active enzymes in humans! Harris, Petersen-Mahrt & Neuberger, 2002, Mol. Cell Petersen-Mahrt, Harris & Neuberger, 2002, Nature
44 Burns, et al. Nature 494: PMID:
45 High A3B Levels Shorten Response To Tamoxifen Law, et al. Sci Adv 2:e PMID:
46 A3B levels associated with overall survival in tamoxifen treatment of advanced breast cancer No Previous Adjuvant/Metastatic Treatment Law, et al. Sci Adv 2:e PMID:
47 What Have We Learned About Breast Cancer? Basic research fuels new ideas New ideas are translated into new therapies, almost always first evaluated in metastatic breast cancer Breast cancer is many diseases one size does not fit all Identifying fuel, drivers, and Achilles heels of disease will result in new strategies and combinations Stopping tumor mutation could enhance duration of response to existing therapies
48 Thanks! Patients Scientists Clinicians Elected officials Advocates
Multimedia Appendix 6 Educational Materials Table of Contents. Intervention Educational Materials Audio Script (version 1)
Multimedia Appendix 6 Educational Materials Table of Contents Intervention Educational Materials... 1 Audio Script (version 1)... 1 Text (version 1)... 5 Slides (version 1)... 17 Audio Script (version
More informationMetastatic Breast Cancer What is new? Subtypes and variation?
Metastatic Breast Cancer What is new? Subtypes and variation? Anne Blaes, MD, MS University of Minnesota, Division of Hematology/Oncology Director, Adult Cancer Survivor Program Current estimates for metastatic
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, for early-stage triple-negative breast cancer, 740 742 in older early-stage breast cancer patients, 790 795 anti-her2-directed
More information6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
More informationRecent Update in Management of Breast Cancer: Medical Oncology. Jin Hee Ahn, M.D., PhD. 23-April-2015
2015 GBCC & 4 th IBCS 1/37 Recent Update in Management of Breast Cancer: Medical Oncology Jin Hee Ahn, M.D., PhD. 23-April-2015 Department of Oncology, Asan Medical Center, UUCM, Seoul, Korea 2/37 3/37
More informationOvercoming resistance to endocrine or HER2-directed therapy
Overcoming resistance to endocrine or HER2-directed therapy Jane Lowe Meisel, MD Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute at Emory University 1 Background While most
More informationMetastatic breast cancer: sequence of therapies
Metastatic breast cancer: sequence of therapies Clinical Case Discussion Nadia Harbeck, MD PhD Breast Center, Department of Gynecology and Obstetrics University of Munich, Ludwig-Maximilians University
More informationThe efficacy of second-line hormone therapy for recurrence during adjuvant hormone therapy for breast cancer
517734TAM6210.1177/1758834013517734Therapeutic Advances in Medical OncologyR Mori and Y Nagao research-article2013 Therapeutic Advances in Medical Oncology Original Research The efficacy of second-line
More informationMechanisms of Resistance to. Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center
Mechanisms of Resistance to Hormonal Therapy Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center Antagonizing Estrogen Dependent Growth Premenopausal
More informationOutline of the presentation
Outline of the presentation Breast cancer subtypes and classification Clinical need in estrogen-positive (ER+) metastatic breast cancer (mbc) Sulforaphane and SFX-01: the preclinical evidence STEM Phase
More informationAdjuvant Systemic Therapy in Early Stage Breast Cancer
Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington
More informationDisease Update: Metastatic Breast Cancer
Disease Update: Metastatic Breast Cancer Aimee Faso, PharmD, BCOP, CPP Oncology Clinical Specialist, GI/Breast UNC Hospitals and Clinics August 2015 Objectives Identify treatment choices of metastatic
More informationMechanisms of hormone drug resistance
Mechanisms of hormone drug resistance Ljiljana Stamatović Institute for Oncology and Radiology of Serbia Tenth UMOS Conference, Belgrade, 16-17 th May 2015. Hormone receptor-positive breast cancer (HR+
More informationTreatment of Metastatic Breast Cancer. Prof RCCoombes Imperial College London
Treatment of Metastatic Breast Cancer Prof RCCoombes Imperial College London Metastatic Breast Cancer: General Guidelines Specialized oncology nurses (if possible specialized breast nurses) should be part
More informationWhat is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland Outline Early breast cancer Advanced breast cancer Open questions Outline Early breast cancer
More informationMdi Medical Management of Breast Cancer Morbidity and Mortality Aug 13, 2009 Irina Kovatch, PGY3 Introduction Metastatic disease is the principal cause of death from breast cancer Metastatic events often
More informationTreatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic Therapy
Women s Empowerment Cancer Advocacy Network (WE CAN) Conference Bucharest, Romania October 2015 Treatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic
More informationTargeting CDK 4/6. Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine
2016.04.30 GBCC Education Symposium Targeting CDK 4/6 Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine Contents Cyclins -CDKs in cell cycle control CDK 4/6 in breast cancer Preclinical
More informationJosé Baselga, MD, PhD
i n t e r v i e w José Baselga, MD, PhD Dr Baselga is Physician-in-Chief at Memorial Sloan-Kettering Cancer Center in New York, New York. Tracks 1-15 Track 1 Track 2 Track 3 Track 4 Track 5 Track 6 Track
More informationPredicting outcome in metastatic breast cancer
Predicting outcome in metastatic breast cancer Aleix Prat, MD, PhD Medical Oncology Department Translational Genomics and Targeted Therapeutics in Solid Tumors Monday, 15 th January, Manchester, UK Disclosures
More informationProgress in the management of metastatic breast cancer in 2018: Is a cure in the horizon?
Progress in the management of metastatic breast cancer in 2018: Is a cure in the horizon? By Gerardo Colón-Otero, MD Mayo Clinic Florida Address correspondence to: Gerardo Colón-Otero, MD Professor of
More informationJohns Hopkins Clinical Update Webinar
Johns Hopkins Clinical Update Webinar Ben Ho Park, M.D., Ph.D. Department of Oncology Johns Hopkins University February 2015 This presentation is the intellectual property of the author/presenter. Contact
More informationWhen is Chemotherapy indicated in Advanced Luminal Breast Cancer?
When is Chemotherapy indicated in Advanced Luminal Breast Cancer? Soo-Chin Lee Head & Senior Consultant Department of Haematology-Oncology Clinical Care National University Cancer Institute, Singapore
More informationEndocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it?
Endocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it? ET1 ET2 ET3 Targeted agent 1 Targeted agent 2 Hope S. Rugo, MD Director, Breast Oncology and Clinical Trials Education
More informationSYSTEMIC THERAPY OPTIONS FOR BREAST CANCER IN 2014
SYSTEMIC THERAPY OPTIONS FOR BREAST Oncology Day 2014 CANCER IN 2014 Dr. Katherine Enright, M.D., M.P.H., F.R.C.P.(C) Katherine.enright@Trilliumhealthpartners.ca OBJECTIVES 1. Outline an approach to the
More informationRadiation therapy Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. Chemotherapy Chemotherapy is a cancer
More informationUpdate on Systemic Treatment of Breast Cancer
Update on Systemic Treatment of Breast Cancer Christoph C. Zielinski Clinical Division of Oncology Department of Medicine I and Comprehensive Cancer Center (www.ccc.ac.at) Medical University Vienna - General
More informationOUTLINE PAST PRESENTFUTURE BREAST CANCER INCIDENCE AND MORTALITY CURRENT STATE OF MEDICAL ONCOLOGY SECOND ANNUAL BREAST CANCER SYMPOSIUM
OUTLINE CURRENT STATE OF MEDICAL ONCOLOGY SECOND ANNUAL BREAST CANCER SYMPOSIUM October 11, 2014 SARA M GARRIDO, M.D., F.A.C.P Chief Medical Officer at AMS Miami, October 11, 2014 PAST PRESENTFUTURE -BRIEF
More information10/15/2012. Overcoming Endocrine Therapy Resistance. The Problem in ER+ Tumors is Endocrine Therapy Resistance
Overcoming Endocrine Therapy Resistance Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology Slide Credits: Hope Rugo, MD The Problem in ER+ Tumors is Endocrine Therapy Resistance
More information14,30 18,20. II Sessione. Moderatori: Giovanni Apolone, Roberto Labianca
14,30 18,20 II Sessione Moderatori: Giovanni Apolone, Roberto Labianca 14,30 14,50 Ca mammario: attualità e prospettive di ricerca Luca Livraghi Carcinoma mammario: attualità e prospettive di ricerca LUCA
More informationGenomic tests to personalize therapy of metastatic breast cancers. Fabrice ANDRE Gustave Roussy Villejuif, France
Genomic tests to personalize therapy of metastatic breast cancers Fabrice ANDRE Gustave Roussy Villejuif, France Future application of genomics: Understand the biology at the individual scale Patients
More informationUpdate on New Perspectives in Endocrine-Sensitive Breast Cancer. James R. Waisman, MD
Update on New Perspectives in Endocrine-Sensitive Breast Cancer James R. Waisman, MD Nothing to disclose DISCLOSURE TAILORx Oncotype Recurrence Score TAILORx Study Design Sparano, J Clin Oncol 2008;26:721-728
More informationPro: Hormone Therapy in HR positive MBC is the preferred option!
Pro: Hormone Therapy in HR positive MBC is the preferred option! Alexandru Eniu, MD, PhD Medical Oncologist Head, Day Hospital Unit Department of Breast Tumors Cancer Institute Ion Chiricuţă Cluj-Napoca,
More informationMetasta&c Breast Cancer 2018
Metasta&c Breast Cancer 2018 November 2, 2018 Douglas W. Blayney, MD Professor of Medicine, Stanford University School of Medicine Stanford Cancer Ins&tute 1 Disclosures Research support to Stanford Amgen
More informationDisclosures. Objectives. Novel Agents in the Systemic Management of Breast Cancer (Breast Cancer Update 2012) Peter Kabos, MD
Mountain States Cancer Conference 2012 Novel Agents in the Systemic Management of Breast Cancer (Breast Cancer Update 2012) Peter Kabos, MD University of Colorado Denver Disclosures No relevant disclosures
More informationLa via del segnale PI3K/AKT/mTOR Inibitori di mtor nel carcinoma mammario
La via del segnale PI3K/AKT/mTOR Inibitori di mtor nel carcinoma mammario Alessandra Modena U.O.C. Oncologia Medica Direttore: Dott.ssa Stefania Gori Ospedale Sacro Cuore - Don Calabria 29 novembre 2016
More informationNovel Strategies in Systemic Therapies: Overcoming Endocrine Therapy Resistance
Novel Strategies in Systemic Therapies: Overcoming Endocrine Therapy Resistance Richard S. Finn, MD Division of Hematology/ Oncology Director, Translational Oncology Laboratory Geffen School of Medicine
More informationBreast Cancer. Dr. Andres Wiernik 2017
Breast Cancer Dr. Andres Wiernik 2017 Agenda: The Facts! (Epidemiology/Risk Factors) Biological Classification/Phenotypes of Breast Cancer Treatment approach Local Systemic Agenda: The Facts! (Epidemiology/Risk
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationTRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer
TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer Marta Bonotto Department of Oncology University Hospital of Udine TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive
More informationUse of Ovarian Suppression and Ablation in Breast Cancer Treatment
Use of Ovarian Suppression and Ablation in Breast Cancer Treatment Dr Marina Parton Consultant Medical Oncologist Royal Marsden and Kingston Hospitals Overview Breast cancer phenotypes Use of ovarian manipulation
More informationAggiornamenti tra ricerca e clinica: il carcinoma della mammella
Aggiornamenti tra ricerca e clinica: il carcinoma della mammella Filippo Montemurro Unit of (INCO) Fondazione del Piemonte per l Oncologia Candiolo Cancer Institute (IRCCs) Research Needs in Breast Cancer
More informationManejo do câncer de mama RH+ na adjuvância: o que há de novo?
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico Manejo do câncer de mama RH+ na adjuvância: o que há de novo? INGRID A. MAYER, MD, MSCI Assistant Professor of Medicine Director,
More informationEndocrine Therapy for Advanced Breast Cancer (ABC) Dr Yoon-Sim YAP Division of Medical Oncology, National Cancer Centre Singapore
Endocrine Therapy for Advanced Breast Cancer (ABC) Dr Yoon-Sim YAP Division of Medical Oncology, National Cancer Centre Singapore Outline Guidelines and Evolving Clinical Treatment Landscape for HR+ HER2-
More informationState-of-the-Art Update: CDK4/6 Inhibitors in ER+ Metastatic Breast Cancer
State-of-the-Art Update: CDK4/6 Inhibitors in ER+ Metastatic Breast Cancer Neil Vasan, MD, PhD, and Maura N. Dickler, MD Abstract Cell-cycle inhibition is a new standard-of-care therapy in estrogen-receptor
More information10/15/2012. Biologic Subtypes of TNBC. Topics. Topics. Histopathology Molecular pathology Clinical relevance
Biologic Subtypes of TNBC Andrea L. Richardson M.D. Ph.D. Brigham and Women s Hospital Dana-Farber Cancer Institute Harvard Medical School Boston, MA Topics Histopathology Molecular pathology Clinical
More informationSystemic Management of Breast Cancer
Systemic Management of Breast Cancer Why Who When What How long Etc. Vernon Harvey Rotorua, June 2014 Systemic Management of Breast Cancer Metastatic Disease Adjuvant Therapy Aims of therapy Quality of
More informationEndocrine treatment might NOT be the preferred option in Hrpos MBC. Dr. Mircea Dediu Sanador Hospital Bucharest Summer School Bucharest 2015
Endocrine treatment might NOT be the preferred option in Hrpos MBC Dr. Mircea Dediu Sanador Hospital Bucharest Summer School Bucharest 2015 Overall survival not improved by the AI treatment Benefit in
More informationEmerging Advances in Metastatic Breast Cancer
Emerging Advances in Metastatic Breast Cancer Bryan P. Schneider, MD Assistant Professor of Medicine & Medical Molecular Genetics IU Simon Cancer Center AT LEAST THREE types of breast cancer TNBC HER2+
More informationOpen Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD
Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD Hanahan and Weinberg, 2000 Acquired Capabilities of Cancer Clinical Trials When should I consider a clinical trial? How do I find the right
More informationDennis J Slamon, MD, PhD
I N T E R V I E W Dennis J Slamon, MD, PhD Dr Slamon is Professor of Medicine, Chief of the Division of Hematology/Oncology and Director of Clinical and Translational Research at UCLA s David Geffen School
More informationMetastasi viscerali: altre opzioni oltre la chemioterapia. Ormonoterapia e Agentianti-Her2. - Valentina Sini -
Metastasi viscerali: altre opzioni oltre la chemioterapia. Ormonoterapia e Agentianti-Her2 - Valentina Sini - Metastatic Breast Cancer ER- Her2-20% ER- Her2+ ER+ Her2+ 5% 15% ER+ Her2- ER+ Her2+ ER- Her2+
More informationContemporary Classification of Breast Cancer
Contemporary Classification of Breast Cancer Laura C. Collins, M.D. Vice Chair of Anatomic Pathology Professor of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA Outline
More informationUpdates From San Antonio Breast Cancer Symposium 2017
Updates From San Antonio Breast Cancer Symposium 2017 Rob Coleman University of Sheffield Presentation Outline New Insights into adjuvant endocrine treatment Duration of treatment Perioperative therapy
More informationCurrent Optimal Sequence and Duration of Endocrine Treatment
[Symposium 7] Present and Future of Endocrine Therapy 07 Apr, 2018@GBCC Current Optimal Sequence and Duration of Endocrine Treatment Breast Oncology Center The Cancer Institute Hospital of JFCR Shinji
More informationManagement of hormone-receptor positive human epidermal receptor 2 negative advanced or metastatic breast cancers
Review Article Page 1 of 10 Management of hormone-receptor positive human epidermal receptor 2 negative advanced or metastatic breast cancers Roger K. C. Ngan Department of Clinical Oncology, Queen Elizabeth
More informationBreast cancer. Prof Arlene Chan Medical Oncologist Director Breast Clinical Trials Unit, Mount Hospital Vice-Chair Breast Cancer Research Centre - WA
Breast cancer rof Arlene Chan Medical Oncologist Director Breast Clinical Trials Unit, Mount Hospital Vice-Chair Breast Cancer Research Centre - WA Breast cancer Incidence of Breast Cancer by Stage at
More informationTargeting mtor pathway in ER+/Her2- breast cancers. Fabrice ANDRE Gustave Roussy
Targeting mtor pathway in ER+/Her2- breast cancers Fabrice ANDRE Gustave Roussy Outline mtor pathway Clinical development of rapalogs in breast cancer Moving beyond rapalogs mtor pathway LKB1 Ras-raf-
More informationA vision for HER2 future
School of Medical Oncology Department of Medical and Biological Sciences - University of Udine Department of Oncology - University Hospital of Udine A vision for HER2 future Current therapeutic algorithm
More informationSubtype-directed therapy of TNBC Global Breast Cancer Conference 2015 & 4th International Breast Cancer Symposium Jeju Island, Korea, April 2015
Subtype-directed therapy of TNBC Global Breast Cancer Conference 2015 & 4th International Breast Cancer Symposium Jeju Island, Korea, April 2015 Ruth M. O Regan, MD Visiting Professor and Division Chief
More informationUnderstanding and Optimizing Treatment of Triple Negative Breast Cancer
Understanding and Optimizing Treatment of Triple Negative Breast Cancer Edith Peterson Mitchell, MD, FACP Clinical Professor of Medicine and Medical Oncology Program Leader, Gastrointestinal Oncology Department
More informationIt is a malignancy originating from breast tissue
59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast
More informationUK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin
UK Interdisciplinary Breast Cancer Symposium Should lobular phenotype be considered when deciding treatment? Michael J Kerin Professor of Surgery National University of Ireland, Galway and Galway University
More informationCustomizing Therapeutic Strategies in the Management of Metastatic Breast Cancer
Customizing Therapeutic Strategies in the Management of Metastatic Breast Cancer Vandana G Abramson, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Breast Cancer
More informationDieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
What is hot in breast cancer brain metastases? Dieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands 8th Annual Brain Metastases Research and Emerging Therapy
More informationSystemic Treatment of Breast Cancer. Hormone Therapy and Chemotherapy, Curative and Palliative
Systemic Treatment of Breast Cancer Hormone Therapy and Chemotherapy, Curative and Palliative Systemic Therapy Invasive breast cancers Two forms Curative Palliative Curative Systemic Therapy Adjuvant Therapy
More informationRuth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory University, Chief of
Endocrine Therapy of Advanced Breast Cancer School of Breast Oncology November 9 th 2013 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology,
More informationAs our understanding of the biology of breast
Targeted therapies forge ahead in multiple breast cancer subtypes Jane de Lartigue, PhD As our understanding of the biology of breast cancer has improved, treatment has become increasingly personalized.
More informationPI3K/AKT/mTOR Inhibitors in Breast Cancer
PI3K/AKT/mTOR Inhibitors in Breast Cancer Dr Yoon-Sim YAP Division of Medical Oncology, National Cancer Centre Singapore Global Breast Cancer Conference 2015 Outline Overview of PI3K/Akt/mTOR Pathway Rationale
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informationBREAST CANCER. Dawn Hershman, MD MS. Medicine and Epidemiology Co-Director, Breast Program HICCC Columbia University Medical Center.
BREAST CANCER Dawn Hershman, MD MS Florence Irving Assistant Professor of Medicine and Epidemiology Co-Director, Breast Program HICCC Columbia University Medical Center Background Breast cancer is the
More informationBreast Cancer: ASCO Poster Review
Breast Cancer: ASCO Poster Review Carmen Criscitiello, MD, PhD Istituto Europeo di Oncologia Milano HER2+ SUBTYPE Research questions in early HER2+ BC De-escalation of toxicity without compromising efficacy
More informationmtor e le altre vie di trasduzione del segnale: Implicazioni cliniche Giampaolo Tortora
mtor e le altre vie di trasduzione del segnale: Implicazioni cliniche Giampaolo Tortora Cattedra di Oncologia Medica UOC Oncologia Medica du Facoltà di Medicina e Chirurgia e Azienda Ospedaliera Universitaria
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationInibitori delle chinasi ciclino dipendenti nel trattamento della malattia metastatica HR-positiva Gli studi clinici
Inibitori delle chinasi ciclino dipendenti nel trattamento della malattia metastatica HR-positiva Gli studi clinici Laura Orlando UOC Oncologia & Breast Unit Brindisi Verona 22/04/2016 Summary Studi con
More informationNewly diagnosed with metatastic disease: where do we go from here? Rick Michaelson Saint Barnabas Medical Center
Newly diagnosed with metatastic disease: where do we go from here? Rick Michaelson Saint Barnabas Medical Center A Diagnosis of Advanced Breast Cancer Leads To Many Immediate Questions How am I supposed
More informationNovità e sequenze terapeutiche nel carcinoma mammario HER2 positivo Terapia neoadiuvante Claudio Zamagni
Novità e sequenze terapeutiche nel carcinoma mammario HER2 positivo Terapia neoadiuvante Claudio Zamagni Direttore SSD Oncologia Medica Addarii Policlinico S.Orsola-Malpighi Bologna Open questions in HER2+
More informationI SOTTOGRUPPI FENOTIPICI E I RISULTATI SINORA RAGGIUNTI. Marta Bonotto Department of Oncology, University Hospital of Udine, Italy
I SOTTOGRUPPI FENOTIPICI E I RISULTATI SINORA RAGGIUNTI Marta Bonotto Department of Oncology, University Hospital of Udine, Italy Breast Cancer Metastatic Breast Cancer (MBC) Metastatic Breast Cancer (MBC)
More informationPresenter: Dr. Suman Rao May 13, 2016
Presenter: Dr. Suman Rao May 13, 2016 1 2010 Breast Cancer Estimates 207,090 NEW CASES 4% Melanoma of Skin 2% Thyroid 31% Breast 13% Lung & Bronchus 2% Pancreas 11% Colon & Rectum 4% Ovary 6% Uterus 3%
More informationTriple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008
Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008 Triple Negative Breast Cancer 15% 25% Triple Negative 20% HER2+ ER+ Low Grade
More informationKinome Profiling: The Potential in ER-Negative Patients. Charles M. Perou, Ph.D. Departments of Genetics and Pathology
Kinome Profiling: The Potential in ER-Negative Patients Charles M. Perou, Ph.D. Departments of Genetics and Pathology Lineberger Comprehensive Cancer Center University of North Carolina Chapel Hill, North
More informationGene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA
Gene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA When Are Biomarkers Ready To Use? Same Rules for Gene Expression Panels Key elements
More informationTranscript and References
Richard S. Finn, MD Associate Professor of Medicine Division of Hematology/Oncology Co-director, Signal Transduction and Therapeutics Program Jonsson Comprehensive Cancer Center Geffen School of Medicine
More informationASCO 2017 BREAST CANCER HIGHLIGHTS
Post-ASCO 24 th June 2017, Dolce La Hulpe, Belgium ASCO 2017 BREAST CANCER HIGHLIGHTS Martine J. Piccart-Gebhart, MD, PhD Jules Bordet Institute, Brussels, Belgium Université Libre de Bruxelles Breast
More informationCLINICAL TRIALS ACC. Jul 2016
CLINICAL TRIALS ACC Jul 2016 Glioblastoma BRAIN A071102 A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
More informationNew Approaches in Breast Cancer Treatment. Tamara Shenkier, MDCM, FRCPC Medical Oncologist, BC Cancer, Vancouver
New Approaches in Breast Cancer Treatment Tamara Shenkier, MDCM, FRCPC Medical Oncologist, BC Cancer, Vancouver Disclosures Advisory board/honorarium (commercial): Genomic Health NanoString Clinical trial
More informationThis is an Open Access document downloaded from ORCA, Cardiff University's institutional repository:
This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: http://orca.cf.ac.uk/103187/ This is the author s version of a work that was submitted to / accepted
More informationIntro to Cancer Therapeutics
An Intro to Cancer Therapeutics Christopher R. Chitambar, MD Professor of Medicine Division of Hematology & Oncology Froedtert and Medical College of Wisconsin Clinical Cancer Center cchitamb@mcw.edu Intro
More informationBreast Cancer Carcinogenesis: Mechanisms and Pathways in Hormone Receptor Positive Disease
Breast Cancer Carcinogenesis: Mechanisms and Pathways in Hormone Receptor Positive Disease 1 Nearly Two-Thirds of Metastatic Breast Cancers Express Hormone Receptors Breast cancer tumors are often classified
More informationBest of San Antonio 2008
Best of San Antonio 2008 Ellie Guardino, MD/PhD Assistant Professor Stanford University BIG 1 98: a randomized double blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant
More information"BRCAness," PARP and the Triple-Negative Phenotype
"BRCAness," PARP and the Triple-Negative Phenotype Prof Alan Ashworth, FRS Disclosures for Professor Alan Ashworth, FRS Consulting Agreements GlaxoSmithKline, Pfizer Inc Patent AstraZeneca Pharmaceuticals
More informationBreast cancer classification: beyond the intrinsic molecular subtypes
Breast cancer classification: beyond the intrinsic molecular subtypes Britta Weigelt, PhD Signal Transduction Laboratory CRUK London Research Institute Summary Breast cancer heterogeneity Molecular classification
More informationCase #2: Hormonal Therapy for Advanced Premenopausal Breast Cancer
Case #2: Hormonal Therapy for Advanced Premenopausal Breast Cancer Fellow Presenter: Katherine Clifton, MD Faculty Discussant: Debu Tripathy, MD 7 th Annual June 1, 2018 Topics to Be Discussed: Staging
More informationESMO SUMMIT MIDDLE EAST 2018
ESMO SUMMIT MIDDLE EAST 2018 Breast Clinical Cases Presentation Hampig Raphael Kourie, MD, MSc, MBioethics Faculty of Medicine, Saint Joseph University of Beirut, Lebanon 6-7 April 2018, Dubai, UAE CONFLICT
More informationENFERMEDAD AVANZADA Qué hacemos con el triple negativo? Nuevas aproximaciones
ENFERMEDAD AVANZADA Qué hacemos con el triple negativo? Nuevas aproximaciones Javier Cortes, Hospital Universitario Ramon y Cajal, Madrid Vall d Hebron Institute of Oncology (VHIO), Barcelona Triple Negative
More informationHighlights of. Metastatic & Advanced Breast Cancer
Highlights of Metastatic & Advanced Breast Cancer 1 Financial Disclosure(s) I currently have or have had the following relevant financial relations to disclose: Speaker s Bureau: Novartis 2 Off Label Use
More informationFirst-in-Class CDK4/6 Inhibitor Palbociclib Could Usher in a New Wave of Combination Therapies for HR+, HER2 Breast Cancer
First-in-Class CDK4/6 Inhibitor Palbociclib Could Usher in a New Wave of Combination Therapies for HR+, HER2 Breast Cancer Jack McCain In February 2015, the Food and Drug Administration (FDA) approved
More informationASCO 2018 Breast Cancer updates. June 29 th 2018 Einav Gal-Yam Sheba MC
ASCO 2018 Breast Cancer updates June 29 th 2018 Einav Gal-Yam Sheba MC Early BC Adjuvant Chemotherapy benefit in HR-pos Nneg BC TAILORX Slide 1 Presented By Joseph Sparano at 2018 ASCO Annual Meeting TAILORx
More informationQuestion 1 A. ER-, PR-, HER+ B. ER+, PR+, HER2- C. ER-, PR+, HER2- D. ER-, PR-, HER2- E. ER-, PR+, HER2+
Triple Negative Breast Cancer Laura C. Collins, M.D. Department of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA Question 1 The tumor depicted on the next slide
More informationTITLE: HER2/neu Antisense Therapeutics in Human Breast Cancer. CONTRACTING ORGANIZATION: Washington University School of Medicine St.
AD Award Number: DAMD17-99-1-9436 TITLE: HER2/neu Antisense Therapeutics in Human Breast Cancer PRINCIPAL INVESTIGATOR: Jeffrey A. Drebin, M.D., Ph.D. CONTRACTING ORGANIZATION: Washington University School
More information